Expertise in
5
conditions

Andrew S. Protheroe

Oxford, ENG, GB 
Expertise in
5
conditions
Oxford, ENG, GB 

Overview

Andrew Protheroe practices practicing medicine in Oxford, United Kingdom.

Mr. Protheroe is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Testicular Cancer, Prostate Cancer, Bladder Cancer, Orchiectomy, and Cystectomy.

He is actively involved in clinical research, co-authoring 94 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Oxford, ENG, United Kingdom
Other Locations
King's College London And Guy's And St. Thomas' NHS Foundation Trust, St. James's University Hospital, Derby, Weston Park Hospital, Portsmouth, Musgrove Park Hospital, Hull, Mount Vernon Cancer Centre, Manchester, ENG, United Kingdom
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase I/II Open Label Non-randomised Safety and Efficacy Study of the Viral Vectored ChAd-MVA 5T4 Vaccine in Combination With PD-1 Checkpoint Blockade in Low- or Intermediate-risk Localized or Locally Advanced Prostate Cancer and Advanced Metastatic Prostate Cancer
Phase I/II Open Label Non-randomised Safety and Efficacy Study of the Viral Vectored ChAd-MVA 5T4 Vaccine in Combination With PD-1 Checkpoint Blockade in Low- or Intermediate-risk Localized or Locally Advanced Prostate Cancer and Advanced Metastatic Prostate Cancer
Enrollment Status: Terminated
Publish Date: June 25, 2025
Intervention Type: Drug, Biological
Study Drugs: ChAdOx1-MVA 5T4 vaccine, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
A Parallel Group Phase I/II Marker Lesion Study to Assess the Safety, Tolerability and Efficacy of Intravenous or Intravesical Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer
A Parallel Group Phase I/II Marker Lesion Study to Assess the Safety, Tolerability and Efficacy of Intravenous or Intravesical Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer
Enrollment Status: Terminated
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin
A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin
Enrollment Status: Completed
Publish Date: May 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

94 Total Publications

The PRAGMATIC pathway - PRostate cancer diAGnosis and MAnagement Triage In Clinical care.
The PRAGMATIC pathway - PRostate cancer diAGnosis and MAnagement Triage In Clinical care.
Journal: BJU international
Published: February 26, 2026

Frequently Asked Questions about Andrew S. Protheroe

Is Andrew S. Protheroe a top-rated expert for Testicular Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Andrew S. Protheroe is classified as an Distinguished expert for Testicular Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Andrew S. Protheroe participate in research or clinical trials?

Yes. Andrew S. Protheroe has published 94 articles and abstracts on conditions like Testicular Cancer. You can view a list of Andrew S. Protheroe's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Protheroe's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile